|
Asian Journal of Andrology (2013) 15, 231β235; doi:10.1038/aja.2012.116; published online 4 February 2013
An elevated serum miR-141 level in patients with bone-metastatic prostate cancer is correlated with more bone lesions
Hai-Liang Zhang, Xiao-Jian Qin, Da-Long Cao, Yao Zhu, Xu-Dong Yao, Shi-Lin Zhang, Bo Dai and Ding-Wei Ye
Department of Urology, Fudan University Shanghai Cancer Center, Shanghai 200032, China
Correspondence: DW Ye, (dwyeli@yahoo.com.cn)
Received 17 June 2012; Revised 14 July 2012; Accepted 11 September 2012
Advance online publication 4 February 2013
| Abstract |
The skeleton is the most common metastatic organ in patients with prostate cancer (PCa). Non-invasive biomarkers that can facilitate the detection and monitoring of bone metastases are highly desirable. We designed this study to assess the expression patterns of serum miR-141 in patients with bone-metastatic PCa. Serum samples were collected to measure the miR-141 level in 56 patients, including six with benign prostatic hyperplasia (BPH), 20 with localized PCa and 30 with bone-metastatic PCa (10 with hormone-naive PCa, 10 with hormone-sensitive PCa and 10 with hormone-refractory PCa). A bone scan was performed for each patient with PCa to assess the number of bone lesions. The quantification of serum miR-141 levels was assayed by specific TaqMan qRT-PCR. The results showed that serum miR-141 levels were elevated in patients with bone metastasis (P<0.001). There was no statistically significant difference in the serum miR-141 levels between patients with BPH and patients with localized PCa. Using Kendall's bivariate correlation test, both the Gleason score and the number of bone-metastatic lesions were found to correlate with serum miR-141 levels (P=0.012 and P<0.001, respectively). The serum miR-141 level was found to be positively correlated with alkaline phosphatase (ALP) level in patients with skeletal metastasis, using Pearson's bivariate correlation test. No relationship was found between the serum miR-141 level and the serum prostate-specific antigen (PSA) level. We concluded that serum miR-141 levels are elevated in patients with bone-metastatic PCa and that patients with higher levels of serum miR-141 developed more bone lesions. Furthermore, serum miR-141 levels are correlated with serum ALP levels but not serum PSA levels.
Keywords: alkaline phosphatase (ALP); biological markers; bones; metastasis; microRNAs; miR-141; prostate-specific antigen (PSA); prostatic neoplasms; serum |
|
